Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PRTA's Cash to Debt is ranked higher than
82% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. PRTA: No Debt )
PRTA' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.96
PRTA's Equity to Asset is ranked higher than
98% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PRTA: 0.96 )
PRTA' s 10-Year Equity to Asset Range
Min: 0.91   Max: 0.98
Current: 0.96

0.91
0.98
Interest Coverage No Debt
PRTA's Interest Coverage is ranked higher than
78% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PRTA: No Debt )
PRTA' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 28.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -8.66
PRTA's Operating margin (%) is ranked higher than
81% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. PRTA: -8.66 )
PRTA' s 10-Year Operating margin (%) Range
Min: -5980.33   Max: -978.44
Current: -8.66

-5980.33
-978.44
Net-margin (%) -10.39
PRTA's Net-margin (%) is ranked higher than
81% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. PRTA: -10.39 )
PRTA' s 10-Year Net-margin (%) Range
Min: -6064.5   Max: -1004.18
Current: -10.39

-6064.5
-1004.18
ROE (%) -2.39
PRTA's ROE (%) is ranked higher than
84% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. PRTA: -2.39 )
PRTA' s 10-Year ROE (%) Range
Min: -68.99   Max: -27.35
Current: -2.39

-68.99
-27.35
ROA (%) -2.28
PRTA's ROA (%) is ranked higher than
85% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. PRTA: -2.28 )
PRTA' s 10-Year ROA (%) Range
Min: -1640.13   Max: -26.31
Current: -2.28

-1640.13
-26.31
ROC (Joel Greenblatt) (%) -126.31
PRTA's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. PRTA: -126.31 )
PRTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2303.58   Max: -1195.18
Current: -126.31

-2303.58
-1195.18
» PRTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PRTA Guru Trades in Q4 2013

Jim Simons 64,600 sh (New)
Vanguard Health Care Fund 902,524 sh (+261.55%)
» More
Q1 2014

PRTA Guru Trades in Q1 2014

Vanguard Health Care Fund 1,327,524 sh (+47.09%)
Jim Simons 79,112 sh (+22.46%)
» More
Q2 2014

PRTA Guru Trades in Q2 2014

Leon Cooperman 100,000 sh (New)
Paul Tudor Jones 30,549 sh (New)
Vanguard Health Care Fund 1,662,794 sh (+25.26%)
Jim Simons 51,900 sh (-34.4%)
» More
Q3 2014

PRTA Guru Trades in Q3 2014

Vanguard Health Care Fund 1,662,794 sh (unchged)
Paul Tudor Jones Sold Out
Leon Cooperman 80,000 sh (-20%)
Jim Simons 17,300 sh (-66.67%)
» More
» Details

Insider Trades

Latest Guru Trades with PRTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2014-06-30 New Buy0.03%$18.73 - $39.62 $ 21.38-15%100000
Vanguard Health Care Fund 2014-06-30 Add 25.26%0.02%$18.73 - $39.62 $ 21.38-15%1662794
Vanguard Health Care Fund 2014-03-31 Add 47.09%0.04%$24.65 - $48.3 $ 21.38-33%1327524
Vanguard Health Care Fund 2013-12-31 Add 261.55%0.05%$19.93 - $29.04 $ 21.38-15%902524
Michael Price 2013-06-30 Sold Out 0.02%$6.6 - $13.71 $ 21.38130%0
Michael Price 2013-03-31 New Buy0.02%$5.84 - $7.33 $ 21.38236%21746
George Soros 2012-12-31 Sold Out $6.8 - $6.9 $ 21.38212%0
Michael Price 2012-12-31 Sold Out $6.8 - $6.9 $ 21.38212%0
Robert Bruce 2012-12-31 Sold Out $6.8 - $6.9 $ 21.38212%0
Ray Dalio 2012-12-31 Sold Out $6.8 - $6.9 $ 21.38212%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.80
PRTA's P/B is ranked higher than
91% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. PRTA: 1.80 )
PRTA' s 10-Year P/B Range
Min: 0.84   Max: 5.16
Current: 1.8

0.84
5.16
P/S 9.50
PRTA's P/S is ranked higher than
82% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. PRTA: 9.50 )
PRTA' s 10-Year P/S Range
Min: 8.31   Max: 900.25
Current: 9.5

8.31
900.25
PFCF 157.10
PRTA's PFCF is ranked higher than
91% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRTA: 157.10 )
PRTA' s 10-Year PFCF Range
Min: 139.62   Max: 186.46
Current: 157.1

139.62
186.46
EV-to-EBIT -57.78
PRTA's EV-to-EBIT is ranked higher than
82% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRTA: -57.78 )
PRTA' s 10-Year EV-to-EBIT Range
Min: -348.9   Max: 0.9
Current: -57.78

-348.9
0.9
Current Ratio 30.97
PRTA's Current Ratio is ranked higher than
98% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. PRTA: 30.97 )
PRTA' s 10-Year Current Ratio Range
Min: 12.51   Max: 72.16
Current: 30.97

12.51
72.16
Quick Ratio 30.97
PRTA's Quick Ratio is ranked higher than
98% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. PRTA: 30.97 )
PRTA' s 10-Year Quick Ratio Range
Min: 12.51   Max: 72.16
Current: 30.97

12.51
72.16

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.00
PRTA's Price/Net Cash is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. PRTA: 2.00 )
PRTA' s 10-Year Price/Net Cash Range
Min: 1.05   Max: 4.56
Current: 2

1.05
4.56
Price/Net Current Asset Value 2.00
PRTA's Price/Net Current Asset Value is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. PRTA: 2.00 )
PRTA' s 10-Year Price/Net Current Asset Value Range
Min: 1.04   Max: 4.51
Current: 2

1.04
4.51
Price/Tangible Book 1.90
PRTA's Price/Tangible Book is ranked higher than
93% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. PRTA: 1.90 )
PRTA' s 10-Year Price/Tangible Book Range
Min: 1   Max: 4.35
Current: 1.9

1
4.35
Price/Median PS Value 0.30
PRTA's Price/Median PS Value is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. PRTA: 0.30 )
PRTA' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 18.29
Current: 0.3

0.29
18.29
Earnings Yield (Greenblatt) -1.70
PRTA's Earnings Yield (Greenblatt) is ranked higher than
83% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. PRTA: -1.70 )
PRTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.7   Max: 74709.2
Current: -1.7

-1.7
74709.2

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PT.Germany,
Prothena Corporation PLC was incorporated in Ireland as a private limited company under the name Neotope Corporation Limited on September 26, 2012. On November1, 2012, it changed the name of the company to Prothena Corporation plc. It is a biotechnology company engaged in the discovery and development of novel antibodies for the potential treatment of an array of diseases that involve protein misfolding or cell adhesion. Its research and development pipeline includes three main therapeutic antibody programs: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 (formerly NEOD002) for the treatment of Parkinson's disease; and PRX003 for the potential treatment of inflammatory disease and metastatic cancers. Its pipeline also includes two late discovery stage programs: tau antibodies for potential treatment of Alzheimer's disease and antibodies for the potential treatment of type 2 diabetes. The competitors consist of major international companies, all of which are larger and have greater financial resources, technical staff, manufacturing, R&D and marketing capabilities. It also competes with smaller research companies and generic drug and biosimilar manufacturers. It is subject to significant regulation by international, national, state and local governmental regulatory agencies.
» More Articles for PRTA

Headlines

Articles On GuruFocus.com
Three Stocks With Massive Insider Buying Sep 03 2014 

More From Other Websites
Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of... Dec 16 2014
BUZZ-U.S. Stocks on the Move-Talisman Energy, Boeing, Healthcare Trust, Russian ADRs Dec 16 2014
PROTHENA CORP PLC Files SEC form 8-K, Other Events Dec 15 2014
Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of... Dec 15 2014
Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of... Dec 15 2014
Global renal biomarkers market player Prothena sees initial success with NEOD001 drug Dec 14 2014
HTML PDF Dec 10 2014
Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York Dec 08 2014
Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York Dec 08 2014
Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York Dec 08 2014
Prothena Corporation (PRTA) Falls: Stock Goes Down 5% Dec 04 2014
Record territory again for the Dow Industrials Dec 03 2014
PROTHENA CORP PLC Files SEC form 8-K, Other Events Dec 03 2014
Prothena Corporation PLC Conference Call to Review Results from NEOD001 Phase 1-2 Study and Designs... Dec 02 2014
Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing... Dec 02 2014
PROTHENA CORP PLC Files SEC form 8-K, Other Events Dec 02 2014
Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing... Dec 02 2014
Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing... Dec 02 2014
Why You Shouldn't Bet Against Prothena Corporation (PRTA) Stock Dec 01 2014
PROTHENA CORP PLC Financials Nov 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK